BMS at the 63rd ASH Annual Meeting & Exposition
Delivering transformative research across major hematologic diseases
Intended for U.S. scientific audiences only.
The American Society of Hematology (ASH) annual meeting is the premier event in malignant and non-malignant hematology, and we remain ever-committed to researching and innovating for the blood cancer community. We look forward to sharing new data that demonstrate the strength of our innovative therapeutic platforms and modalities across our pipeline and portfolio in a broad range of hematologic diseases.
Hear from Chief Medical Officer Samit Hirawat, M.D. and President of Research and Early Development Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. about the ways we’re working together to deliver transformative research across the most difficult-to-treat hematologic diseases, advancing care and improving patients’ lives.
Our Data at ASH
Read more about our key data being presented at ASH.
Our Dedication to Advancing Cell Therapy, A Novel Personalized Medicine
Cell therapy, which includes therapies comprised of cells that are injected, implanted or grafted to treat disease, and use engineered cells to unlock new potential in the fight against cancer, is one of several key areas of research at Bristol Myers Squibb. Learn more about our dedication to cell therapies and personalized medicine here:
Over the last several decades, our innovative medicines have improved how cancer is treated, making long-term survival a possibility for more patients. But there is more work to do, and we strive to help more patients with our medicines, scientific discovery and investigational research. Learn about our approach.
Our Commitment to Hematological Cancers
We are committed to improving the lives of patients and raising awareness of hard-to-treat blood cancers. We’ve brought life-changing medicines to patients worldwide and redefined treatment across many hematologic conditions. However, hundreds of thousands of patients still lack treatment options or their treatments have stopped working. For these patients, we keep innovating. Learn more here:
Possibly the only thing more frightening than being diagnosed with cancer is learning you have a form of the disease you’ve never heard of. Patients with MDS — a little-known blood cancer — are searching for new Myelodysplastic Syndrome treatment options.
Hear from Chief Medical Officer Samit Hirawat, MD on how Bristol Myers Squibb has helped patients overcome barriers to clinical trial participation and advanced its R&D pipeline during the global pandemic.
Our research at ASH this year spans multiple blood cancers, therapeutic platforms, and clinical programs. Learn more about some of them below.
Disease State and Treatment Infographics
Download infographic resources on different types of blood cancers and therapies.